Table 1.
Demographics, patient baseline characteristics, co‐morbidities, and cardiovascular risk factors in 50 patients with newly diagnosed pulmonary arterial hypertension (PAH) undergoing rapid sequential combination therapy
| All (n = 50) | Classical PAH (n = 37) | PAH with co‐morbidities (n = 13) | P‐value | |
|---|---|---|---|---|
| Patient characteristics | ||||
| Age, years (means ± SD) | 54.5 ± 18.9 | 49.8 ± 18.9 | 67.8 ± 10.7 | <0.001 |
| Age, years (median, Q1–Q3) | 57 (42–71) | 50 (30–68) | 68 (65–76) | <0.001 |
| Gender, m/f (%) | 34/66 | 30/70 | 46/54 | 0.3219 |
| Type of PAH: | ||||
| Idiopathic, n (%) | 38 (76.0%) | 27 (73.0%) | 11 (84.6%) | 0.480 |
| Hereditary, n (%) | 2 (4.0%) | 2 (5.1%) | 0 (0.0%) | 1 |
| Drug‐induced, n (%) | 2 (4.0%) | 1 (2.6%) | 1 (9.1%) | 0.456 |
| Connective tissue disease, n (%) | 7 (14.0%) | 6 (15.4%) | 1 (9.1%) | 0.660 |
| Congenital heart disease, n (%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 |
| HIV, n (%) | 1 (2.0%) | 1 (2.6%) | 0 (0.0%) | 1 |
| Other, n (%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 |
| Co‐morbidities/CV risk factors | ||||
| Hypertension, n (%) | 29 (58.0%) | 17 (46.0%) | 12 (92.3%) | 0.004 |
| Diabetes, n (%) | 12 (24.0%) | 3 (8.1%) | 9 (69.2%) | <0.001 |
| Dyslipidaemia, n (%) | 9 (18.0%) | 3 (8.1%) | 6 (46.2%) | 0.006 |
| CAD, n (%) | 7 (14.0%) | 2 (5.4%) | 5 (38.5%) | 0.009 |
| BMI > 30 kg/m2, n (%) | 17 (34.0%) | 8 (20.5%) | 9 (69.2%) | 0.005 |
Distributions of qualitative variables were compared by the Fisher's exact test.
BMI, body mass index; CAD, coronary artery disease; CV, cardiovascular; PAH, pulmonary arterial hypertension.